The European Commission has begun a public stakeholder consultation which will feed into the interim evaluation of Horizon 2020, the EU’s €77 billion research and innovation funding scheme running from 2014 to 2020.
H2o2o has already funded several epilepsy-focused, and other neurological, research projects. More information on these projects can be found on EpilepsyAllianceEurope.org.
The interim evaluation of Horizon 2020 will be an important element in preparations of a next EU research and innovation programme.
Carlos Moedas, European Commissioner for Research, Science and Innovation, said: “I hope as many people as possible will use the chance to have their say on Horizon 2020, its first three years and its future direction. We are already analysing available data, facts and figures. But in order to have a full overview, it is very important to get direct feedback from researchers, entrepreneurs, innovators, citizens and all types of organisations that have participated in the programme.”
Horizon 2020 is one of the largest research and innovation schemes worldwide. In its first two years, the programme attracted over 76,000 eligible proposals. Over 9,000 grant agreements were signed by September 1, 2016 for calls with deadlines in 2014 and 2015, allocating almost €16 billion to boosting excellent science, creating industrial leadership and tackling societal challenges.
The public stakeholder consultation on the interim evaluation of Horizon 2020 will be open until 15 January 2017.